Solid Tumors MGMT Methylation

O⁶-methylguanine methyltransferase (MGMT) gene encodes a DNA repair enzyme that de-alkylates guanines in DNA. Methylation of CpG sites in the promoter region of the MGMT gene leads to decreased expression of this enzyme, allowing accumulation of alkylguanines that, following incorrect base pairing with thymine, cause DNA damage signaling and cell death.  

MGMT promoter methylation predicts for increased sensitivity of gliomas to alkylating agents like BCNU (carmustine), and also correlates with prolonged progression-free survival in temozolomide treated patients.

1. Microscopic examination of the specimen and macrodissection of tumor-rich areas.
2. DNA extraction and purification.
3. Bisulfite treatment of the DNA.
4. Methylation-specific PCR for selected regions of the MGMT gene promoter region.

• A paraffin block or
• 10 unstained sections of tumor (4-5 microns)(15 sections for small biopsies). 

Contact Client Services for shipping materials and procedures at (855) 535-1522.

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Mon – Fri

7-10 calendar days

• Keep specimen cool during transit. Do not ship on dry ice.
• Please use the cold pack provided in the KDL shipping kit.
• Ship the specimen overnight express, using the FedEx priority overnight label provided. 
• Contact Client Services for shipping materials and procedures at (855) 535-1522.

1. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. British Journal of Cancer 2009;101:124-131.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66.